Synopsis:- Shares hit a 2% upper circuit after a 3:2 bonus issue announcement, improving liquidity and investor interest. Trading near Rs 349 with a Rs 239 crore market cap, the move comes alongside expansion plans, 450+ product pipeline, and stable margins, supporting long-term growth visibility.
The shares of this pharmaceutical company hit a 2 percent upper circuit in today’s trading session after the company had inter alia considered and approved a bonus issue in the ratio of 3:2.
With a market capitalization of Rs 239.62 crore, the shares of Aptus Pharma Ltd were trading at Rs 349.30 per share, increasing around 1.97 percent as compared to the previous closing price of Rs 342.55 apiece.
Bonus Issue
The shares of Aptus Pharma Ltd have seen positive movement after the board of directors considered and recommended the issue of Bonus Equity Shares in the ratio of 3:2 i.e., 3 (Three) bonus equity shares for every 2 (Two) existing fully paid-up equity shares held by the Members
of the Company, subject to the approval of the members of the company. For example, 100 shares will become 250 shares post-issue. While it does not impact overall value, it improves liquidity.
Financial & other Highlights
The company delivered strong growth, with revenue rising 47% from Rs 9.76 crore to Rs 14.38 crore, reflecting improving business momentum. Net profit also increased 34% from Rs 1.31 crore to Rs 1.75 crore, indicating better earnings. However, profit growth lagged revenue, suggesting some margin pressure despite overall expansion in operations.
Over the past year, Aptus Pharma’s operating performance has improved steadily. Operating profit increased from Rs 1.98 crore in Sep 2024 to Rs 2.93 crore in Sep 2025, reflecting better scale and execution. Meanwhile, OPM remained stable at around 20.3%, indicating consistent margins despite growth, suggesting balanced cost management alongside expanding operations.
Aptus Pharma Ltd has outlined an ambitious Vision 2026–30, focusing on expansion and diversification. The company plans to launch 450+ products across 25+ therapeutic segments while strengthening its PAN-India presence. Additionally, it aims to expand globally, enter new states, and adopt a franchise model, indicating a strong push toward scalable growth and market penetration.
Recently, at first glance, Aptus Pharma Ltd’s IPO delivered a modest listing performance. The stock was issued at Rs 70 and listed at Rs 80.80, offering a gain of Rs 10.80 or 15.43%. With a minimum investment of Rs 2.6 lakh and a lot size of 2,000 shares, the Rs 13.02 crore issue saw a decent market debut.
Aptus Pharma is involved in the marketing and distribution of finished pharmaceutical formulations. Its product range covers multiple therapeutic areas, including anti-infective, gastrointestinal, antacid, anti-allergic, and respiratory, nutritional supplements, pain management, neuropsychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness treatments.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 3:2 Bonus Issue: Pharma Stock Hits Upper Circuit After Board Approves Bonus Issue appeared first on Trade Brains.